RxDoctor Payments Data

Daniel Stewart, DO

Cardiovascular Disease · Dalton, GANPI 1992082838

Payments from drug & device makers

$1,753in general payments, 2019–2025

Across 103 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$667
  • Pfizer$160
  • Johnson & Johnson$119
  • E.r. Squibb & Sons, L.L.C.$118
  • Edwards Lifesciences$100
  • AstraZeneca$95
  • plus $495 from 16 others

What the payments were for

  • Food & beverage$1,753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,753 in reported general payments places this provider in the 40th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$149,266
Medicare patients
690
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$220,463
EntrestoSacubitril/Valsartan112$97,275
JardianceEmpagliflozin139$94,367
FarxigaDapagliflozin Propanediol96$77,308
XareltoRivaroxaban27$30,595
Repatha SureclickEvolocumab26$24,875
Fenofibrate16$7,966
BrilintaTicagrelor12$7,877
Ranolazine ErRanolazine37$2,646
Metoprolol Succinate182$2,168
Rosuvastatin Calcium138$1,611
Spironolactone211$1,307
Carvedilol214$1,108
Isosorbide Mononitrate ErIsosorbide Mononitrate76$1,009
Atorvastatin Calcium106$866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$220,463243 claims
NovartisEntresto$667$97,275112 claims
Boehringer IngelheimJardiance$59$94,367139 claims
AstraZenecaFarxiga, Brilinta$95$85,185108 claims
Johnson & JohnsonXarelto$119$30,59527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →